Tvax Biomedical LLC

TVAX Biomedical is a biotechnology company focused on innovative cancer therapies, particularly through its TVAX Immunotherapy® platform, which uses personalized T cell therapy to combat cancer. TVAX Biomedical develops personalized cancer therapies leveraging the TVAX Immunotherapy® platform. Located in Lenexa, US, the company was founded by Wayne Carter, who has a history in biotechnology. TVAX Biomedical raised USD 2.

00 mn in funding on March 30, 2015, with a total amount raised of USD 2. 00 mn across 3 deals. TVAX Biomedical specializes in developing personalized cancer therapies, with the TVAX Immunotherapy® platform as its core offering. This involves a two-step treatment that extracts T cells from the patient's blood post-vaccination with neoantigen-producing cancer cells.

The lead candidate, TVI-Brain-1, is under evaluation for glioblastoma treatment, targeting unmet medical needs in oncology for healthcare providers and patients across the US, while exploring markets in Europe and Asia. TVAX Biomedical operates on a business model centered on clinical trials and partnerships for its proprietary treatments. Revenue is derived from collaborations with pharmaceutical firms, research institutions, and clinical trial sponsorships, allowing the advancement of clinical studies and regulatory approvals. Key revenue sources include milestone payments, licensing agreements, and future sales from successful FDA-approved therapies, particularly focusing on TVI-Brain-1 for partnerships in clinical trials and commercialization.

TVAX Biomedical aims to advance its product pipeline, particularly focusing on the TVI-Brain-1 candidate, while exploring additional offerings in immunotherapy. The company is also considering expansion into European and Asian markets by 2025. The recently raised USD 2. 00 mn will support these growth initiatives, enhancing clinical trial capabilities and regulatory strategies.